Results based on sensitivity analyses of retrieved dropout population. SUSTAIN 5 and SUSTAIN FORTE were only powered to detect differences in weight from baseline to Week 30 and Week 40, respectively.
The estimated treatment difference was from baseline to Week 30 for SUSTAIN 5 and from baseline to Week 40 for SUSTAIN FORTE.
SUSTAIN 5: Results are from a 30-week, randomized, double-blind, placebo-controlled, parallel-group trial in 397 adult patients with type 2 diabetes evaluating the addition of Ozempic® 0.5 mg and Ozempic® 1 mg to basal insulin ± metformin.1,6
SUSTAIN FORTE: Results are from a 40-week, randomized, active-controlled trial in 961 adult patients with type 2 diabetes on metformin with or without a sulfonylurea, comparing Ozempic® 1 mg with Ozempic® 2 mg.1,4
MET=metformin; ETD=estimated treatment difference; CI=confidence interval.